Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Melissa L Comstock, Shyril O'Steen, Yukang Lin, Donald Hamlin, D Scott Wilbur, Johnnie J. Orozco, Rainer F. Storb, Roland B. Walter, Pinar Ataca Atilla, Brian G Till, Geoffrey R Hill, Brenda M. Sandmaier, Damian J Green

Blood (2023) 142 (Supplement 1): 53.

https://doi.org/10.1182/blood-2023-188055

Published: 2023

Journal Articles

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Shyril O’Steen, Melissa L. Comstock, Johnnie J. Orozco, Donald K. Hamlin, D. Scott Wilbur, Jon C. Jones, Aimee Kenoyer, Margaret E. Nartea, Yukang Lin, Brian W. Miller, Theodore A. Gooley, Sherilyn A. Tuazon, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, Oliver W. Press, Damian J. Green

Blood (2019) 134 (15): 1247–1256.

https://doi.org/10.1182/blood.2019001250

Published: 2019

Includes: Supplemental data

Journal Articles

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

Shyril O'Steen, PhD, Melissa C. Comstock, BS, Johnnie J. Orozco, MD PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Jon Jones, BS, Aimee Kenoyer, BS, Margaret E. Nartea, BS, Yukang Lin, PhD, Brian W. Miller, PhD, Sherilyn A. Tuazon, MD, Brian G. Till, MD, Ajay K. Gopal, MD, Brenda M. Sandmaier, MD, Oliver W. Press, MD PhD, Damian J. Green, MD

Blood (2018) 132 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2018-99-119555

Published: 2018

Journal Articles

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Damian J. Green, Shyril O’Steen, Yukang Lin, Melissa L. Comstock, Aimee L. Kenoyer, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Margaret Nartea, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Kelly D. Orcutt, K. Dane Wittrup, Oliver W. Press

Blood (2018) 131 (6): 611–620.

https://doi.org/10.1182/blood-2017-09-807610

Published: 2018

Includes: Supplemental data

Journal Articles

Novel Bispecific Antibody Targeting CD45 and 90 Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models

Johnnie J. Orozco, MD PhD, Aimee Kenoyer, BS, Yukang Lin, PhD, Darrell R. Fisher, PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Alexandra Hernandez, BS, Rosario Guel, Margaret E. Nartea, Shyril O'Steen, PhD, Mark D Hylarides, PhD, Brian G Till, MD, Damian J. Green, MD, Ajay K. Gopal, MD, Kelly D Orcutt, PhD, Karl Dane Wittrup, PhD, Brenda M. Sandmaier, MD, John M. Pagel, MD PhD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 1355.

https://doi.org/10.1182/blood.V130.Suppl_1.1355.1355

Published: 2017

Journal Articles

Venetoclax Synergizes with Radiation Therapy for Treatment of B-Cell Lymphomas

Shyril O'Steen, PhD, Amelia Waltman, Garrett Booth, Aimee L Kenoyer, BS, Margaret Nartea, Chelsea Mullins, Yukang Lin, Sang Yun Lee, Mark D Hylarides, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Oliver W Press, MD PhD

Blood (2016) 128 (22): 467.

https://doi.org/10.1182/blood.V128.22.467.467

Published: 2016

Journal Articles

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Blood (2015) 126 (23): 118.

https://doi.org/10.1182/blood.V126.23.118.118

Published: 2015

Journal Articles

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model

Blood (2015) 125 (13): 2111–2119.

https://doi.org/10.1182/blood-2014-11-612770

Published: 2015

Includes: Supplemental data

Journal Articles

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

Aimee L. Kenoyer, BS, Yukang Lin, PhD, Johnnie J. Orozco, MD PhD, Ethan Balkin, Don Hamlin, BS, Alexandra H. Hernandez, BS, Chen Fang, PhD, Kelly Laird, Sofia H.L. Frost, PhD, Mark Hylarides, PhD, Kelly D. Orcutt, PhD, D Scott Wilbur, PhD, K. Dane Wittrup, PhD, Oliver W. Press, MD PhD, John Pagel, MD PhD

Blood (2014) 124 (21): 3749.

https://doi.org/10.1182/blood.V124.21.3749.3749

Published: 2014

Journal Articles

Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model

Damian J. Green, MD, Mazyar Shadman, MD, MPH, Shani L. Frayo, BS, Jon C. Jones, Mark D. Hylarides, PhD, Aimee L. Kenoyer, BS, D. Scott Wilbur, PhD, Donald K. Hamlin, BS, Yukang Lin, PhD, Ajay K. Gopal, MD, Sofia H.L. Frost, PhD, Johnnie J. Orozco, MD, PhD, John M. Pagel, MD, PhD, Oliver W. Press, MD, PhD

Blood (2013) 122 (21): 4415.

https://doi.org/10.1182/blood.V122.21.4415.4415

Published: 2013

Journal Articles

Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model

Damian J. Green, MD, Jon C. Jones, Mark D. Hylarides, PhD, Donald K. Hamlin, BS, D Scott Wilbur, PhD, Yukang Lin, PhD, Aimee L. Kenoyer, BS, Shani L. Frayo, BS, William I. Bensinger, MD, Ajay K. Gopal, MD, Johnnie J. Orozco, MD, PhD, Theodore A. Gooley, PhD, Brent L. Wood, MD, PhD, John M. Pagel, MD, PhD, Oliver W. Press, MD, PhD

Blood (2013) 122 (21): 882.

https://doi.org/10.1182/blood.V122.21.882.882

Published: 2013

Journal Articles

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal, David G. Maloney, Catherine G. Lindgren, Yukang Lin, John M. Pagel, Lihua E. Budde, Andrew Raubitschek, Stephen J. Forman, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press

Blood (2012) 119 (17): 3940–3950.

https://doi.org/10.1182/blood-2011-10-387969

Published: 2012

Includes: Supplemental data

Journal Articles

Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model

Damian J. Green, MD, Nural N. Orgun, Mark D. Hylarides, PhD, John M. Pagel, MD, PhD, Donald K. Hamlin, D. Scott Wilbur, PhD, Yukang Lin, PhD, Amiee L. Kenoyer, Shani L. Frayo, BS, William I. Bensinger, MD, Ajay K. Gopal, MD, Johnnie J. Orozco, MD, PhD, Theodore A. Gooley, PhD, Brent L. Wood, MD, PhD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 1842.

https://doi.org/10.1182/blood.V118.21.1842.1842

Published: 2011

Journal Articles

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

John M. Pagel, Aimee L. Kenoyer, Tom Bäck, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Steven I. Park, Shani Frayo, Amanda Axtman, Nural Orgun, Johnnie Orozco, Jaideep Shenoi, Yukang Lin, Ajay K. Gopal, Damian J. Green, Frederick R. Appelbaum, Oliver W. Press

Blood (2011) 118 (3): 703–711.

https://doi.org/10.1182/blood-2011-04-347039

Published: 2011

Journal Articles

Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma

Brian G. Till, MD, Michael C. Jensen, MD, Xiaojun Qian, Jinjuan Wang, Ajay K Gopal, MD, David G. Maloney, Catherine G. Lindgren, Yukang Lin, John M. Pagel, MD, PhD, Lihua E Budde, MD., PhD, Andrew Raubitschek, MD, Stephen Forman, Philip Greenberg, Stanley R. Riddell, MD, Oliver W. Press, MD, PhD

Blood (2010) 116 (21): 561.

https://doi.org/10.1182/blood.V116.21.561.561

Published: 2010

Journal Articles

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Steven I. Park, Jaideep Shenoi, John M. Pagel, Don K. Hamlin, D. Scott Wilbur, Nural Orgun, Aimee L. Kenoyer, Shani Frayo, Amanda Axtman, Tom Bäck, Yukang Lin, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, Oliver W. Press

Blood (2010) 116 (20): 4231–4239.

https://doi.org/10.1182/blood-2010-05-282327

Published: 2010

Journal Articles

Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice

Scott E. James, Nural N. Orgun, Thomas F. Tedder, Mark J. Shlomchik, Michael C. Jensen, Yukang Lin, Philip D. Greenberg, Oliver W. Press

Blood (2009) 114 (27): 5454–5463.

https://doi.org/10.1182/blood-2009-08-232967

Published: 2009

Includes: Supplemental data

Journal Articles

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Steven I. Park, MD, Jaideep Shenoi, MD, John M. Pagel, MD, PhD, Donald K. Hamlin, Nural Orgun, Aimee L. Kenoyer, Shani M. Wilbur, BS, Amanda Axtman, D. Scott Wilbur, PhD, Yukang Lin, PhD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2009) 114 (22): 2705.

https://doi.org/10.1182/blood.V114.22.2705.2705

Published: 2009

Journal Articles

Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.

Aimee L. Kenoyer, BS, Oliver W. Press, MD, PhD, Steven I. Park, MD, Tom Back, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Shani M. Wilbur, BS, Amanda Axtman, BS, Nural Orgun, Yukang Lin, PhD, Ajay K. Gopal, MD, Jaideep Shenoi, MD, Damian J. Green, MD, Frederick R Appelbaum, John M. Pagel, MD, PhD

Blood (2009) 114 (22): 1035.

https://doi.org/10.1182/blood.V114.22.1035.1035

Published: 2009

Journal Articles

Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates

Damian J. Green, John M. Pagel, Eneida R. Nemecek, Yukang Lin, Aimee Kenoyer, Anastasia Pantelias, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Joseph G. Rajendran, Ajay K. Gopal, Steven I. Park, Oliver W. Press

Blood (2009) 114 (6): 1226–1235.

https://doi.org/10.1182/blood-2009-03-210344

Published: 2009

NARROW

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Novel Bispecific Antibody Targeting CD45 and 90 Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models

Venetoclax Synergizes with Radiation Therapy for Treatment of B-Cell Lymphomas

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

Astatine-211 Conjugated To Anti-CD20 Monoclonal Antibody Eliminates B-Cell Lymphoma In a Mouse Model

Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice

Conventional and Pretargeted Radioimmunotherapy with Bismuth-213 to Target and Treat CD20-Expressing Non-Hodgkin Lymphoma: A Preclinical Model for Consolidation Therapy to Eradicate Minimal Residual Disease.

Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.

Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only